... good two weeks ago, it's a sell due to rising raw costs. The company trades at 22 times its earnings, but is only growing at 10%, and that makes it too expensive in Cramer's book. Cramer put PharMerica PMC in the "don't buy" camp. This company is too new and unseasoned to invest in, he said, adding he saw no compelling reason to take on the extra risk. Cramer didn't think Clorox CLX was a ...

http://community.livejournal.com/cramermadmoney/168573.html
0 links
Published: 1 year, 5 months ago (Sun, 10 Feb 2008 14:23:39 PST); 4719 bytes
|